Literature DB >> 15753474

A prospective analysis of immunohistochemically determined estrogen receptor alpha and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog.

J Martín de Las Mulas1, Y Millán, R Dios.   

Abstract

The immunohistochemically determined estrogen receptor (ER) alpha (ERalpha) and progesterone receptor (PR) status, as well as recognized, well-accepted prognostic indicators and host factors were prospectively analyzed in 84 cases of primary canine mammary carcinoma for their effect on disease-free period (recurrence free, metastasis free, or combined) (DFP) after an observation period of 18 months. The presence of one or both receptors, as well as tumor size, lymph node status, histologic grading, intravascular growth, and necrosis, were of prognostic value for DFP. In multivariate analysis, only tumor size and histologic grading proved to be independent prognosticators. None of the host factors analyzed were of prognostic value for DFP. ERalpha, PR, or both were detected in 173 out of 228 tumors: 70 ERalpha and PR; 5 ERalpha only; 98 PR only. Statistically significant differences regarding the presence of one or both receptors were observed between benign and malignant tumors and between complex, mixed, and simple histologic subtypes of benign and malignant tumors. In the group of malignant tumors (n=155), the presence of one or both receptors was more frequent in tumors smaller than 3 cm, without lymph node metastasis, with tubulopapillary rather than solid patterns of growth among simple carcinomas, of histologic grades I and II, without both intravascular growth and necrosis, and with lymphocyte cell infiltrates. The most frequent groups of hormone receptors-positive tumors were the ERalpha-positive and PR-positive group among benign and the ERalpha-negative and PR-positive group among malignant tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15753474     DOI: 10.1354/vp.42-2-200

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  28 in total

1.  Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification.

Authors:  A Gama; A Alves; F Schmitt
Journal:  Virchows Arch       Date:  2008-08-02       Impact factor: 4.064

2.  Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates.

Authors:  Alessandra Estrela-Lima; Márcio S S Araújo; João M Costa-Neto; Andréa Teixeira-Carvalho; Stella M Barrouin-Melo; Sergio V Cardoso; Olindo A Martins-Filho; Rogéria Serakides; Geovanni D Cassali
Journal:  BMC Cancer       Date:  2010-06-04       Impact factor: 4.430

3.  Vitamin D receptor (VDR) expression in different molecular subtypes of canine mammary carcinoma.

Authors:  R Sánchez-Céspedes; M D Fernández-Martínez; A I Raya; C Pineda; I López; Y Millán
Journal:  BMC Vet Res       Date:  2021-05-25       Impact factor: 2.741

4.  Molecular portrait-based correlation between primary canine mammary tumor and its lymph node metastasis: possible prognostic-predictive models and/or stronghold for specific treatments?

Authors:  Germana Beha; Barbara Brunetti; Pietro Asproni; Luisa Vera Muscatello; Francesca Millanta; Alessandro Poli; Giuseppe Sarli; Cinzia Benazzi
Journal:  BMC Vet Res       Date:  2012-11-12       Impact factor: 2.741

5.  Evaluation of adverse effects in tamoxifen exposed healthy female dogs.

Authors:  Wanessa L F Tavares; Gleidice E Lavalle; Mariana S Figueiredo; Aline G Souza; Angelica C Bertagnolli; Fernando A B Viana; Paulo R O Paes; Rubens A Carneiro; Guilherme A O Cavalcanti; Marilia M Melo; Geovanni D Cassali
Journal:  Acta Vet Scand       Date:  2010-12-22       Impact factor: 1.695

6.  Endocrine control of canine mammary neoplasms: serum reproductive hormone levels and tissue expression of steroid hormone, prolactin and growth hormone receptors.

Authors:  Michèle Spoerri; Franco Guscetti; Sonja Hartnack; Alois Boos; Christine Oei; Orsolya Balogh; Renata M Nowaczyk; Erika Michel; Iris M Reichler; Mariusz P Kowalewski
Journal:  BMC Vet Res       Date:  2015-09-15       Impact factor: 2.741

7.  Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry.

Authors:  Francesco Sassi; Cinzia Benazzi; Gastone Castellani; Giuseppe Sarli
Journal:  BMC Vet Res       Date:  2010-01-28       Impact factor: 2.741

8.  An immunohistochemical study on the expression of sex steroid receptors in canine mammary tumors.

Authors:  Leena Rajathy Port Louis; Khub Chandra Varshney; Madhavan Gopalakrishnan Nair
Journal:  ISRN Vet Sci       Date:  2012-02-15

9.  Identification of prognostic factors in canine mammary malignant tumours: a multivariable survival study.

Authors:  Andreia A Santos; Célia C Lopes; Jorge R Ribeiro; Liliana R Martins; Joana C Santos; Irina F Amorim; Fátima Gärtner; Augusto J Matos
Journal:  BMC Vet Res       Date:  2013-01-04       Impact factor: 2.741

10.  Genome aberrations in canine mammary carcinomas and their detection in cell-free plasma DNA.

Authors:  Julia Beck; Silvia Hennecke; Kirsten Bornemann-Kolatzki; Howard B Urnovitz; Stephan Neumann; Philipp Ströbel; Franz-Josef Kaup; Bertram Brenig; Ekkehard Schütz
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.